Inclusion Criteria:

- Patients who FIGO Stage I, II, or III criteria for low-risk gestational trophoblastic
neoplasia (GTN);

- WHO risk score 0-6;

- Age≤60 years; female, Chinese women;

- Initial treatment is chemotherapy; patients who received prior low-dose methotrexate
for treatment of an ectopic pregnancy will be eligible for this study;

- Performance status: Karnofsky score≥60;

- Laboratory tests: WBC≥3.5×10(9)/L, ANC≥1.5×10(9)/L, PLT≥80×10(9)/L, serum bilirubin≤
1.5 times the upper limit of normal, transaminase≤ 1.5 times the upper limit of
normal, BUN, Cr≤ normal

- Provide written informed consent.

Exclusion Criteria:

- Patients with unconfirmed diagnosis of GTN;

- Patients with placental-site trophoblastic tumor (PSTT) or epithelioid trophoblastic
tumor (ETT)

- WHO risk score >6;

- With severe or uncontrolled internal disease, unable to receive chemotherapy;

- Concurrently participating in other clinical trials

- Unable or unwilling to sign informed consents;

- Unable or unwilling to abide by protocol.